Acting FDA commissioner Dr. Ned Sharpless and at least two others are reportedly in the running to lead the federal safety watchdog, including a Harvard dermatology professor and a physician at a Texas cancer center.
Sharpless, the former head of the National Cancer Institute, took over from Dr. Scott Gottlieb as acting commissioner in April. He’s made it clear that he wants “acting” stricken from his title, according to the Wall Street Journal, but faces at least two other potential nominees.
One is Dr. Alexa Boer Kimball, a Harvard dermatology professor and president & CEO of the Harvard Medical Faculty Physicians at Boston’s Beth Israel Deaconess Medical Center, the newspaper reported, citing “people familiar with the situation.”
Another potential candidate is a physician at Houston’s M.D. Anderson Cancer Center, according to the paper.
Dr. Kimball and a spokeswoman for M.D. Anderson declined to comment, as did Sharpless, the Journal reported, calling the acting commissioner the “presumptive favorite.”
A senior administration official said other candidates are also under review to give the president options, according to the Journal.
Integra Lifesciences promotes CFO to COO, taps
Integra LifeSciences (NSDQ:IART) said yesterday that it promoted Glenn Coleman CFO to COO and tapped Carrie Anderson, formerly controller & chief accounting officer at Dover Corp., as Coleman’s replacement.
Nevro lures Abbott Vascular VP, Dermira HR exec
Nevro Corp. (NYSE:NVRO) said it lured Niamh Pellegrini, the former global commercial ops VP for Abbot Vascular, to be its new chief commercial officer. Nevro also said it named Lori Ciano, formerly HR SVP at Dermira, as its chief HR officer.
Theranica staffs up new U.S. subsidiary
Theranica said it sattffed up its newly former U.S. subsidiary in Montclair, N.J., naming Scott Szymanski president of Theranica USA, David Warshawsky as business development & ops VP and Alix Bennett as senior director of medical affairs.